For patients with osteoporosis caused by transfusion-dependent thalassemia (TDT), a twice-yearly injection appears to improve spinal bone mineral density, according to a new study. Osteoporosis is a ...

AUSTIN, Texas – One year of romosozumab (Evenity) followed by 1 year of denosumab (Prolia, Xgeva) was associated with improved bone mineral density (BMD) and lower fracture incidence compared with 2 ...

Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology and central nervous system (CNS) therapies, today announced the ...

Longer durations of denosumab treatment improved the probability of achieving target T-scores at the total hip and lumbar spine in postmenopausal women with osteoporosis. Denosumab treatment ...

A study comparing denosumab (Prolia) with risedronate (Actone) found that denosumab could be a useful treatment option for patients newly initiating or continuing glucocorticoids who are at risk of ...

Science and society collaboration is essential for scientific progress, especially in the health and biomedical fields where basic researchers, clinicians and patients are involved, as shown by the ...

Please provide your email address to receive an email when new articles are posted on . Adults with osteoporosis who received more than one dose of denosumab had a reduced risk for developing diabetes ...

The research and therapeutic options are limited for skeletal abnormalities found in neurofibromatosis type 1 (NF1)—a haploinsufficient and multisystemic disease caused by inherited or sporadic ...

Older women who received denosumab (Prolia, Amgen) for up to 10 years for osteoporosis had a low risk of osteonecrosis of the jaw (ONJ), although the risk was higher — albeit still quite small — if ...

Biosimilar CT-P41 showed comparable efficacy and safety to reference denosumab for treating osteoporosis among postmenopausal women. CT-P41, a biosimilar candidate for denosumab, demonstrates efficacy ...

November 10, 2010 (Atlanta, Georgia) — Denosumab reduces fracture risk and is safe for at least 3 years in older patients with renal impairment, according to results from a phase 3 study. Dr. Jamal’s ...